LHLabcorp Holdings Inc.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Adam H. Schechter

Location

North Carolina, USA

Exchange

NYSE

Website

https://labcorp.com

Summary

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide.

Company Info

CEO

Adam H. Schechter

Location

North Carolina, USA

Exchange

NYSE

Website

https://labcorp.com

Summary

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide.

AI Insights for LH
6 min read

Quick Summary

Labcorp Holdings Inc. is an independent clinical laboratory and diagnostics company headquartered in Burlington, North Carolina. The company provides routine and specialty testing services, including blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, prostate-specific antigen tests, gene-based testing, and other esoteric diagnostics. Its main customers include physicians, hospitals, health systems, employers, pharmaceutical and biotechnology companies, managed care organizations, government programs, and individual patients. Labcorp also supports clinical trials and biopharma research through central laboratory services, pathology capabilities, precision medicine testing, and advanced diagnostic infrastructure. The company operates at large scale, with about 75,500 employees and a business model that depends on testing volume, payer reimbursement, healthcare utilization, and partnerships with health systems.

Strengths

•

Labcorp’s primary strength is its large scale in the clinical laboratory industry, supported by broad test menus, nationwide infrastructure, payer relationships, and extensive physician and health system connections.

•

The company benefits from recurring healthcare demand because diagnostic testing is essential for preventive care, disease diagnosis, chronic condition monitoring, and treatment selection.

•

Its specialty testing and advanced diagnostics capabilities position it to participate in higher-growth areas such as precision medicine, oncology, molecular testing, digital pathology, and clinical trial support.

•

Labcorp’s partnerships with health systems, including recent outreach lab asset deals, can expand access, improve local volume, and deepen customer relationships.

•

The company also has a relatively defensive healthcare profile, a beta below 1.0, and shareholder return support through dividends and buybacks, although the dividend yield is modest.

Key Risks

•

Labcorp faces significant external risk from reimbursement reductions, especially the planned CMS cuts that may begin in 2027 and could lower revenue over multiple years.

•

Regulatory changes, compliance requirements, billing scrutiny, and payer contract negotiations can all affect profitability and create uncertainty.

•

Competitive risks are also meaningful because large diagnostic labs, hospital systems, specialized molecular testing companies, and new consumer health platforms can pressure pricing or capture faster-growing testing categories.

•

Macroeconomic conditions may affect employer testing, discretionary health services, biotech funding, and clinical trial activity, which could influence Labcorp’s growth outlook.

What to Watch

During or near the most recent quarter, Labcorp’s notable developments centered on expansion initiatives and reimbursement concerns rather than officially confirmed Q3 2026 earnings results.
The company completed a transaction with Legacy Health to acquire select outreach laboratory assets in Oregon and Southwest Washington, which should expand Labcorp’s regional diagnostic testing access while Legacy retained ownership of its hospital laboratories.
Labcorp also opened a larger anatomic pathology and histology laboratory in Los Angeles, adding AI-enabled digital pathology and advanced testing capabilities that support clinical trials, precision medicine, oncology, and liver disease research.
A key industry event was the announcement of planned CMS laboratory reimbursement reductions beginning in 2027, which created concern about future pricing and revenue pressure.
Because the next earnings date is listed as October 27, 2026, Q3 2026 financial figures should not be described as officially reported until the company releases results.

Price Drivers

•

Labcorp’s stock price is primarily driven by earnings growth, testing volume, reimbursement trends, operating margins, and management’s revenue outlook.

•

Investors are likely to focus on the company’s upcoming earnings release, listed for October 27, 2026, because that update should clarify recent revenue growth, margin performance, testing demand, and guidance.

•

The provided financial dataset includes operating revenue of about $3.73 billion, total gross profit of about $1.11 billion, total operating income of about $451.6 million, net income of about $299.1 million, diluted EPS of $3.64, and basic EPS of $3.66, but these quarter-specific figures should be interpreted as preliminary or dataset-provided values until confirmed by the official earnings release.

•

Current valuation metrics also matter, with the shares showing a price-to-earnings ratio of about 26.2, an earnings yield of about 3.82%, and an enterprise value to EBITDA ratio of about 14.78.

•

Reimbursement pressure is another major driver: reports of CMS lab reimbursement cuts of up to 15% beginning in 2027 have weighed on sentiment because Medicare-related laboratory payments are meaningful to industry revenue.

•

Other price drivers include health system partnerships, specialty diagnostics growth, clinical trial demand, operating efficiency, share buybacks, dividends, regulatory developments, and broader healthcare sector sentiment.

Recent News

•

Recent news has been mixed for Labcorp, with expansion activity offset by reimbursement concerns.

•

The company completed a deal with Legacy Health to acquire select outreach laboratory assets in the Northwest, expanding diagnostic testing access in Oregon and Southwest Washington while Legacy retained ownership of hospital labs.

•

Labcorp also opened a larger anatomic pathology and histology lab in Los Angeles, strengthening global central lab capabilities with AI-enabled digital pathology and advanced testing for clinical trials, precision medicine, oncology, and liver disease research.

•

Another important news item was the CMS announcement of lab reimbursement cuts of up to 15% beginning January 1, 2027, which pressured laboratory stocks because Medicare reimbursement is an important part of industry economics.

•

Earlier financial reporting also showed full-year 2025 sales of about $13.95 billion and a 2026 revenue outlook of $14.61 billion to $14.79 billion, supported by specialty diagnostics and biopharma investments.

Market Trends

•

The broader diagnostics market is being shaped by demand for preventive testing, chronic disease monitoring, precision medicine, oncology diagnostics, and molecular testing.

•

Liquid biopsy is one of the most important growth trends, with the market expected to grow from about $4.03 billion in 2025 to about $7.05 billion by 2030, driven by noninvasive cancer detection and monitoring.

•

Consumers are also gaining more direct access to testing through health platforms, memberships, and cash-pay services, which may change how some routine and preventive tests are ordered.

•

At the same time, reimbursement pressure remains a major industry trend because governments and payers continue trying to reduce healthcare costs and limit laboratory spending.

•

Large laboratory companies like Labcorp may benefit from scale and consolidation, but they must keep investing in advanced diagnostics, automation, AI-enabled pathology, and health system partnerships to stay competitive.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on LH

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show